B A C K G R O U N D
Malaria is a severe and debilitating disease caused by the parasitic protozoan Plasmodium, which is transmitted by many species of anopheline mosquitoes. Four Plasmodium species infect humans. Plasmodium falciparum is the most widespread and also the most serious and potentially fatal form. Recent estimates of the annual number of clinical malaria cases worldwide range from 214 to 397 million (WHO 2002; Breman 2004) , although a higher estimate of 515 million (range 300 to 660 million) clinical cases of P. falciparum in 2002 has been proposed (Snow 2005) . Estimates of annual mortality (nearly all from P. falciparum malaria) are thought to be around 1.1 million (WHO 2002; Breman 2004) . Malaria deaths are believed to account for 3% of the world's total Disability Adjusted Life Years (DALYs) lost and 10% of DALYs in Africa (Breman 2004) . Malaria also significantly increases the risk of childhood death from other causes (Snow 2004) . Almost half of the world's population live in areas where they are exposed to risk of malaria (Hay 2004) ; increasing numbers of visitors to endemic areas are also at risk.
Despite continued efforts to control malaria, it remains a major health problem in many regions of the world. The number of drugs remaining effective is limited, and new ways to prevent the disease are urgently needed. Currently the major methods used to prevent malaria in endemic areas are impregnated mosquito nets and indoor residual spraying. Vaccines are widely considered a necessary component for the complete success of malaria control, but it is likely that vaccines will need to be used in conjunction with these other methods rather than replacing them completely. Early optimism for vaccines was tempered as the problems caused by genetic (hence, antigenic) variability of the parasite and the difficulty of generating high levels of durable immunity emerged. Recently, hope has been renewed by the development of several new vaccine candidates and delivery systems, as well as new formulations and adjuvants for previously existing candidates (Ballou 2004; Moorthy 2004a) . Vaccines currently under evaluation include recombinant proteins, synthetic peptides (including multiple antigen peptides), DNA vaccines, inactivated whole parasites, and vaccines comprising mixtures of a large variety of potential antigens. All vaccines discussed in this review are candidate vaccines only, since no malaria vaccines are currently licensed in any country.
To be effective, a malaria vaccine could either prevent infection altogether or mitigate against severe disease and death in those who become infected despite vaccination. Four stages of the malaria parasite's life cycle have been the targets of vaccine development efforts. The first two stages are often grouped as 'pre-erythrocytic stages' (ie before the parasite invades the human red blood cells): these are the sporozoites inoculated by the mosquito into the human bloodstream; and the parasites developing inside human liver cells. The other two targets are the stage when the parasite is invading or growing in the red blood cells (blood, merozoite, or erythrocytic stage); and the gametocyte stage, when the parasites emerge from red blood cells and fuse to form a zygote inside the mosquito vector (gametocyte, gamete, or sexual stage). Vaccines based on the pre-erythrocytic stages usually aim to completely prevent infection, while blood-stage vaccines aim to reduce (and preferably eliminate) the parasite load once a person has been infected. Gametocyte vaccines would prevent the parasite being transmitted to others through mosquitoes. Ideally, a vaccine effective at all these parasite stages is desirable (Richie 2002) .
Given the complexity and wide range of malaria vaccines under development, we have chosen to consider them in three categories: pre-erythrocytic vaccines (the subject of this review); SPf66 vaccine; and blood-stage vaccines. Future Cochrane Reviews may consider transmission-blocking and multi-stage vaccines when these are tested. The SPf66 vaccine was the first to be tested extensively (Graves 2006a) . SPf66 was ineffective in Africa (five trials) and Asia (one trial). It had marginal efficacy in South America (four trials). It is no longer being tested and development towards commercialization is not taking place. However, it is possible that new formulations of SPf66 or combinations with other antigens will be developed in the future.
One blood-stage vaccine has advanced to Phase 2 trials, but it showed limited efficacy (Graves 2006b). This is currently a highly active area of research and new blood-stage vaccine trials will be described in future updates of the blood-stage vaccine Cochrane Review as they become available.
Pre-erythrocytic vaccines
This review includes the randomized trials conducted to date on the efficacy of four types of pre-erythrocytic vaccines: CS-NANP; CS102; RTS,S; and ME-TRAP. The CS-NANP-based pre-erythrocytic vaccines were the first to be tested, beginning in the 1980s. The vaccines used in the first trials comprised three different formulations of the four amino acid Bcell epitope NANP, which is present as multiple repeats in the circumsporozoite protein covering the surface of the sporozoites of P. falciparum. The number of NANP repeats in these vaccines varied from three to 19, and three different carrier proteins were used. The CS102 vaccine is also based on the sporozoite CS protein, but it does not include the NANP epitope. It is a synthetic peptide consisting of a stretch of 102 amino acids containing T-epitopes from the C-terminal end of the molecule. The RTS,S recombinant vaccine also includes the NANP epitope. It contains 19 NANP repeats plus the C terminus of the CS protein fused to hepatitis B surface antigen (HBsAg), expressed together with unfused HBsAg in yeast. The resulting construct is formulated with the adjuvant ASO2/A. Thus the vaccine contains a large portion of the CS protein in addition to the NANP region, as well as the hepatitis B carrier. The ME-TRAP vaccine is entirely different from the other pre-erythrocytic malaria vaccines. It is a DNA vaccine that uses the primeboost approach to immunization. It uses a malaria DNA sequence known as ME (multiple epitope)-TRAP (thrombospondin-related protein). The ME string contains 15 T-cell epitopes, 14 of which stimulate CD8 T-cells and the other of which stimulates CD4 Tcells, plus two B-cell epitopes from six pre-erythrocytic antigens of P. falciparum. It also contains two non-malarial CD4 T-cell epitopes and is fused in frame to the TRAP sequence. This sequence is given first as DNA (two doses) followed by one dose of the same DNA sequence in the viral vector MVA (modified vaccinia virus Ankara). Phase 1 studies with this vaccine (excluded from this review) were very promising (McConkey 2003; Bejon 2005) . In addition to the vaccine candidates included in this review, many excluded studies describe Phase 1 trials carried out with other P. falciparum pre-erythrocytic candidates, including other recombinant CS/hepatitis B vaccines (Walther 2005) , sporozoite DNA vaccines (Le 1999), and multiple-antigen peptides (Nardin 2000; Nardin 2001) . Vaccines consisting of killed irradiated P. falciparum sporozoites are also being evaluated (Hoffman 2002) . Those that progress to efficacy trials will be included in future updates of this review.
O B J E C T I V E S
To assess the efficacy and safety of pre-erythrocytic malaria vaccines against any type of human malaria.
Types of studies
Randomized controlled trials.
Types of participants
People of any age.
Types of interventions Intervention
Recombinant, synthetic peptide, parasite-derived, or other vaccines containing antigens only from pre-erythrocytic stages of any species of malaria parasite tested in humans in experimental or natural challenge trials. This currently includes the following vaccines: CS-NANP; CS 102; RTS,S; and ME-TRAP.
Control
Placebo or control vaccine, or routine antimalarial control measures.
Types of outcome measures

Primary
• New malaria infection: Plasmodium appearance in blood sample.
• Clinical malaria episodes.
Secondary
• Severe malaria.
• Prevalence of parasitaemia.
• Parasite density: Plasmodium count from blood sample.
• Fever episodes.
• Anaemia.
• Cerebral malaria.
• Admission to hospital.
• Admission to hospital with diagnosis of malaria.
• Death.
• Adverse events (local and systemic).
Search methods for identification of studies
We have attempted to identify all relevant trials regardless of language or publication status (published, unpublished, in press , and in progress).
Databases
We searched the following databases using the search terms and strategy described in 
Reference lists
We checked the reference lists of all studies identified by the above methods.
Data collection and analysis
Selection of studies
Two people independently applied the inclusion criteria to all identified trials (one author and an Editor of the Cochrane Infectious Diseases Group, or both authors). Differences were discussed until consensus was reached.
Data extraction and management
Both authors independently extracted data on number of each outcome and number of participants from the trials using a prespecified form. Differences were resolved by discussion. Data details were checked with the trial authors for Alonso 2005a and Alonso 2005b.
Assessment of risk of bias in included studies
Both authors independently assessed the trials for four dimensions of quality using a pre-specified form: method of generation of allocation sequence and allocation concealment (adequate, inadequate, not done, or unclear as defined by Jüni 2001); blinding (described who was blinded, eg participants, investigators, and outcome assessors); and completion of follow up (proportion of those randomized who completed all doses and who completed follow up, if stated). Differences were resolved by discussion.
Data synthesis
We analysed the data using Review Manager 5. Results for dichotomous data were expressed as risk ratios (RR) of an outcome occurring in the vaccine group compared to the control group. The risk ratio may be converted to an estimate of vaccine efficacy: efficacy = (1 -RR) x 100%. Similarly, the 95% confidence interval (CI) for the vaccine efficacy may be obtained by substituting the upper and lower 95% confidence intervals of the risk ratio into the formula. Continuous results (parasite density) were expressed as mean difference, using the geometric mean parasite density in positive blood samples. If trials continued after a booster dose, we separated the analysis of these results accordingly. Trials were also subgrouped according to the age of the participants (children versus adults) representing different immune status or transmission conditions, or both, and according to the type of challenge (experimental or natural). This review used an intention-to-treat analysis, that is, the denominators were the numbers randomized into each arm. Many trials included adjusted incidence rates, such as by bed net use or performed time-to-event analysis. This meta-analysis uses only unadjusted incidence rates based on the number of participants in each arm of the trial.
R E S U L T S Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. Nine safety and efficacy trials, and two safety trials, including more than 3000 participants aged between three months and 45 years met the inclusion criteria; see the 'Characteristics of included studies' for detailed information on these trials. In two instances, more than one trial is reported in the same publication (Alonso 2005a and Alonso 2005b; Bojang 2005a and Bojang 2005b) . Nineteen trials were excluded for reasons listed in the ' Characteristics of excluded studies'. The included efficacy trials comprised three of CS-NANP vaccines (Guiguemde 1990; Brown 1994; Sherwood 1996) 
CS-NANP vaccines
Two different constructs containing the NANP epitope of the CS protein were used in the three trials of CS-NANP vaccines. Guiguemde 1990 used three synthetic NANP repeats conjugated to tetanus toxoid; the control was tetanus toxoid. Brown 1994 and Sherwood 1996 used a recombinant vaccine (R32toxA) containing 30 NANP and 2 NVDP repeats conjugated to the toxin A of Pseudomonas aeruginosa with alum. The controls were tetanus/ diphtheria toxoid and hepatitis B vaccine, respectively. Guiguemde 1990 and Sherwood 1996 were conducted in Africa, and Brown 1994 was conducted in Asia. All the CS-NANP trials were conducted in situations of natural challenge. Guiguemde 1990 was carried out with 123 infants (three to five months old) in a highly malaria endemic area. The two trials of R32toxA were in adult males only (199 in Brown 1994; 76 in Sherwood 1996) . In Sherwood 1996, all participants were given a treatment course of quinine/doxycycline before each vaccination. Guiguemde 1990 used active case detection. Brown 1994 used a combination of passive and active (bi-weekly) case detection, while Sherwood 1996 did surveillance by daily home visitation. In the CS-NANP trials in endemic areas, data were reported on clinical and parasitaemic episodes. Clinical malaria was defined as symptoms plus parasitaemia in Guiguemde 1990 and Sherwood 1996. Brown 1994 was conducted in a less endemic area and the outcome measure was parasitaemia. Both Brown 1994 and Sherwood 1996 also used time to infection as an outcome measure and employed survival analysis methods. For this review, the incidence of the first episode of either parasitaemia (if given) or clinical malaria (passive and active detection combined) in each group has been used for analysis. Data from Guiguemde 1990 were reported as the cumulative incidence of parasitaemia over the course of the study. The total number of incident cases was not reported, although some children may have been positive at more than one survey.
CS102 vaccine
CS102 is a synthetic peptide vaccine containing T epitopes from the C-terminal end of the CS protein. Genton 2005, a small trial of CS102 in malaria-naive volunteers in Switzerland with 16 adult participants, allocated 10 participants to vaccine and six to control (adjuvant alone). The trial assessed efficacy using polymerase chain reaction (PCR) to detect parasites in the blood after artificial challenge by infected mosquitoes. (Alonso 2005b) . The control vaccines given in both trials were as follows: children under 24 months were given pneumococcal conjugate vaccine (first and third doses) and Haemophilus influenzae b vaccine (second dose); and children over 24 months were given hepatitis B vaccine in three doses. All children in cohort two were treated with amodiaquine and sulfadoxine-pyrimethamine four weeks before the start of surveillance to clear any parasites.
RTS,S vaccine
Results of the RTS,S Mozambique trials were reported separately for two periods of follow up − six months and 18 months − starting two weeks after the third dose. In this review, the results at six and 18 months are reported separately for some outcome measures (eg prevalence). Bojang 2001 conducted follow up by daily surveillance for 15 weeks in the first year and nine weeks in the second year. In Mozambique, cohort one was followed mainly by passive surveillance, although monthly home visits were also done (Alonso 2005a). Cohort two was followed more intensely by active surveillance for new infections in addition to passive surveillance through health facilities (Alonso 2005b). Follow up for adverse events was reported for the combined cohorts and tabulated under the trial name Alonso 2005ab.
ME-TRAP vaccine
ME-TRAP is a DNA vaccine given in a prime-boost sequence: DNA representing multiple pre-erythrocytic antigen epitopes is given first in two doses followed by DNA inserted in the viral vector MVA (modified vaccinia Ankara). One ME-TRAP trial was conducted with 372 adult males in The Gambia using rabies vaccine in the control group (Moorthy 2004b). All participants were treated with sulfadoxine-pyrimethamine two weeks before the third dose. The follow-up period was 11 weeks after the final dose.
Risk of bias in included studies
CS-NANP vaccines
The method of randomization was not described in any of the three trials, and allocation concealment was described only in Brown 1994. All trials were described as double blind. The withdrawal rate was low (< 10%) in the Sherwood 1996 trial, but between 10% and 20% in Guiguemde 1990 and Brown 1994. The withdrawal rate did not appear to differ between the vaccine and control groups.
CS102 vaccines
Randomization and allocation concealment were both adequate in Genton 2005, and investigators, participants, and outcome assessors were blinded. Two out of 16 participants in the trial did not receive the challenge infection due to previously undisclosed medical histories.
RTS,S vaccines
The RTS,S trials were generally good quality. Both randomization and allocation concealment were adequate in all RTS,S trials except Kester 2001 in which allocation concealment was not used, and all included groups were described as double blind or blinded participants, investigators, and outcome assessors, at least initially. The RTS,S Mozambique trials (Alonso 2005a and Alonso 2005b) technically became single blind after the code was broken and results were reported to investigators after six months follow up. However, only the study statistician held the code, which was not available to other investigators, participants, or assessors, and no further immunizations were given. Therefore, it is unlikely that bias was introduced in the single-blind phase.
In Kester 2001, only 52% of those starting the immunization series were subsequently challenged: 50% of the vaccine groups and 58% of the placebo group. There was a relatively high dropout rate in both arms of Bojang 2001: 14% of the vaccine group and 22% of the control group dropped out or were excluded between the first dose and the follow-up period in the first year. Fifty-two per cent of original participants took part in the second year of the trial (48% of the vaccine group and 56% of the control group).
More than 94% of participants in each of the two trials from The Gambia completed the short follow up (Bojang 2005a; Bojang 2005b) . In Mozambique, follow up was better in Alonso 2005a (cohort one) where 93% received three doses and 86% completed the first six months follow up, than in Alonso 2005b (cohort two) where the proportions were 92% and 72%, respectively. Some participants not present in the double-blind, six-month, followup phase were included in the subsequent single-blind follow up from six to 18 months; over 90% of those entering the singleblind phase completed the follow up in both cohorts.
ME-TRAP vaccine
The one trial of ME-TRAP was of good quality (Moorthy 2004b); it was double blind with adequate allocation concealment. Among 372 randomized participants, 86% received three doses and 80% completed follow up.
Effects of interventions 1. CS-NANP vaccines (3 trials)
There was no evidence for effectiveness of CS-NANP vaccines in the three trials. The combined risk ratio for reduction of new infections in the three trials was 1.05 (95% CI 0.82 to 1.35; 307 participants, Analysis 1.1).
CS102 vaccines (1 trial)
All 14 participants in this small trial of non-immune individuals had malaria infection as detected by PCR (8 participants in the vaccine group, and 6 in the control group; Genton 2005). However, participants in the vaccine group had a significant reduction in the frequency of nausea (RR 0.13, 95% CI 0.02 to 0.78; 14 participants, Analysis 2.1). There were also non-significant reductions in the frequency of fever (14 participants, Analysis 2.2) and malaise (14 participants, Analysis 2.3).
RTS,S vaccines (4 safety/efficacy trials and 2 safety trials)
RTS,S protected strongly against malaria infection in one trial in non-immune people using experimental challenge (RR 0. No effect was seen on anaemia at either survey (Analysis 3.9), but the prevalence of anaemia was low in these study populations. Adverse events were assessed in adults in the USA and The Gambia, and in children in The Gambia and Mozambique (Analysis 3.10). In The Gambia (Bojang 2005a; Bojang 2005b), adverse events were graded on a one to four scale, but the results given represent the numbers of children with any adverse event, not necessarily those with grade three or four reaction. Also in each of these trials, the results from all three vaccine dose groups have been combined. In Mozambique, adverse events were reported for both cohorts one and two combined (cited here as Alonso 2005ab). Severe adverse events are reported by length of follow up: zero to six months; and six to 18 months. Significantly higher proportions of participants in the malaria vaccine groups reported injection site pain, swelling, arm motion limitation, headache, and malaise after vaccination compared with the control groups (Analysis 3.10). The frequency of adverse events was stated to be similar in hepatitis B surface antigen-positive and antigen-negative participants (Bojang 2001), although five hepatitis B virus (HBV) chronic carriers developed elevated alanine amino-tranferase concentrations after vaccination and were not given further vaccinations. After a fourth booster dose, three of 79 vaccine recipients in the Bojang 2001 trial developed severe injection site pain compared with none in the control group. In Bojang 2005a, one child in the vaccine group developed grade-two axillary lymphadenopathy after the first vaccine dose; it resolved within four days. In both safety trials from The Gambia, symptoms rated as grade-three severity were infrequent and resolved or decreased within 24 hours. No severe adverse events believed to be related to vaccination were reported. In Alonso 2005ab, a high frequency of severe events was reported especially during the first six months (RR 0.72, 95% CI 0.61 to 0.85; 1876 participants, Analysis 3.11), but they were less frequent in the malaria vaccine compared with the control groups, and none was judged to be related to vaccination.
ME-TRAP vaccine (1 trial)
There was no evidence for effectiveness of ME-TRAP vaccine in preventing new infections (296 participants, Analysis 4.1) or clinical malaria episodes (296 participants, Analysis 4.2). Nor did the vaccine reduce density of parasites (171 cases, Analysis 4.3) or increase mean packed cell volume (a measure of anaemia) in semiimmune adult males (296 participants, Analysis 4.4) in The Gambia (Moorthy 2004b). Adverse events were significantly more frequent in vaccine than control groups (Analysis 4.5). The frequencies of all types of local and systemic events, except objective fever and nausea, were greater in the vaccine than control groups. However, no serious adverse events were reported.
D I S C U S S I O N
Four different types of pre-erythrocytic vaccine are described in this review. The RTS,S vaccine has shown significant efficacy against both experimental challenge (in non-immunes) and natural challenge (in participants living in endemic areas) with malaria. Children in Mozambique were protected by RTS,S against episodes of clinical malaria and severe malaria in trials in for up to 18 months after immunization. Protection against clinical malaria in these children was estimated at 26% (95% CI 13% to 37%). It is encouraging that RTS,S also showed significant protection against severe malaria in children, estimated at 58% (95% CI 15 to 79%). However the efficacy estimate for severe malaria in the Mozambique RTS,S trial was based on exploratory analyses and more precise estimates are needed. Further trials of RTS,S are in the planning stages. Although no evidence was found for efficacy of RTS,S against clinical malaria in adults in The Gambia in the first year of follow up, efficacy was 63% (95% CI 18% to 93%) in the second year after immunization, after a booster dose. The results from the Mozambique efficacy trial described here are generally consistent with the efficacy results presented in the published papers (Alonso 2005a; Alonso 2005b), which were based on time-to-event analysis and hazard ratios. These estimated that the efficacy of the vaccine (defined as 1 -hazard ratio) was 29.9% against clinical episodes and 57.7% against severe malaria. However for first infection, this review's finding of lack of significant efficacy (1 -risk ratio) against new infection is different from the published paper's estimate, which was 45%, based on a time-toinfection analysis.
Of the three other types of vaccine reviewed, the CS-NANP vaccine has been tested in three relatively small trials under natural challenge, and CS102 has only been tested in one very small good quality trial in non-immune participants using experimental challenge. Evidence is insufficient to evaluate the efficacy of either of these vaccines, although with current evidence they do not appear promising. The ME-TRAP vaccine has also only been tested in one randomized trial, although it was a good quality, large trial in an endemic area.
There are no significant safety issues with RTS,S vaccines, although the frequency of local and systemic adverse events is increased compared to control. No severe adverse events were judged to be vaccine related.
If further trials of RTS,S show similar results to those already reported, the level of protection against severe malaria justifies speedy progression of this vaccine towards licensing for routine use as well as further development of the vaccine for greater efficacy. In addition to exploring efficacy of other pre-erythrocytic antigens and whole irradiated parasites, methods of improving the immunogenicity and effectiveness of the RTS,S vaccine and its combination with DNA vaccines or antigens from other malaria stages are the highest research priorities. In addition, since infants less than one year old are a high-risk population and the future target group for malaria vaccines, RTS,S and other vaccines must be tested in infants.
A U T H O R S ' C O N C L U S I O N S Implications for practice
The RTS,S vaccine showed extremely promising results, especially with regard to prevention of severe malaria in children and duration of protection of 18 months. The frequency of local and systemic adverse events is increased by RTS,S vaccine, but no severe adverse events were judged to be vaccine related. If further trials show similar results to those already reported, these results justify speedy progression of this vaccine towards licensing for routine use as well as further development of the vaccine for greater efficacy. Progression towards licensing should be accompanied by development of deployment strategies, including funding for the countries most in need of the vaccine.
Implications for research
The CS-NANP epitope alone appears to be ineffective in a vaccine. Research on vaccines that combine the NANP epitope with other antigens may be more productive. CS102 and ME-TRAP have not been evaluated sufficiently to make a judgement about their ultimate value. Methods of improving the immunogenicity and effectiveness of the RTS,S vaccine and its combination with DNA vaccines or antigens from other malaria stages are research priorities, as is testing candidate vaccines in infants. Future trials should be designed to detect effects on clinical and severe malaria.
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R E F E R E N C E S C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Alonso 2005a
Methods Randomized controlled trial Generation of allocation sequence: computer generated in blocks of 6 Allocation concealment: central randomization was done at GlaxoSmithKline and the code released to the investigators after completion of follow up; opaque masked and coded syringes were per month starting 60 days after third dose to check residence and document unreported adverse events; complete blood count done 1 month after dose 3; creatinine, alanine aminotransferase (ALT), and bilirubin at months 1 and 6.5 after dose 3; cross-sectional surveys with blood slide and axillary temperature taken at 6.5 months and 18 months after dose 3 This trial reported in same publication as Alonso 2005b
Alonso 2005ab
Methods Study reference created for the reporting of adverse event data, which were reported jointly in the two trial reports ( 
Alonso 2005b
Methods Randomized controlled trial Generation of allocation sequence: computer generated in blocks of 6 Allocation concealment: central randomization was done at GlaxoSmithKline and the code released to the investigators after completion of follow up; opaque and masked coded syringes were used Blinding: investigator, participants, and outcome assessors blinded for first 6 months; investigators were not blinded during next 12 months Inclusion of all randomized participants: 383/417 (91.8%) of those randomized received 3 doses; 299/417 (71.7%) completed 6 months follow up (78.1% of those who received 3 doses); 352 entered single-blind phase of whom 320 (90.9%) completed follow up Length of follow up: 18 months after third dose Participants Number: 417 children Inclusion criteria: age 1 to 4 years; resident in study area; full Expanded Programme of Immunization (EPI) immunization; parent's consent Exclusion criteria: history of allergic disease; packed cell volume ≤ 25%; weight for height ≤ 3 Z score; clinically significant chronic or acute disease; abnormal haematology or biochemistry variables Interventions 1. RTS,S vaccine: 3 doses, 25 µg in 250 µL AS02A adjuvant, intramuscularly in deltoid (alternating arms) at 0, 1, and 2 months 2. 7-valent pneumococcal conjugate vaccine (< 24-months old; doses 1 and 3) plus Hib vaccine (dose 2) or hepatitis B vaccine (> 24-months old; 3 doses) 4 weeks before start of surveillance, presumptive treatment with amodiaquine and sulfadoxine-pyrimethamine was given; those children positive 2 weeks later were treated with second-line drug and excluded from follow up Outcomes 1. Time to first infection with Plasmodium falciparum malaria (case definition: presenting with temperature > 37.5°C and parasitaemia > 2500/µL)
2. Clinical episodes of malaria 3. Malaria needing admission (P. falciparum sole cause of illness or important contributing factor) 4. All-cause admission 5. Severe malaria (derived from World Health Organization definition: asexual P. falciparum parasitaemia; no other more probable cause of illness; plus composite of severe malaria anaemia (packed cell volume < 5%), cerebral malaria (Blantyre coma score < 2), and severe disease of other body systems (multiple seizures, prostration, hypoglycaemia, clinically suspected acidosis, or circulatory collapse) 6. Prevalence of parasitaemia 7. Prevalence of anaemia (packed cell volume < 25%) 8. Geometric mean parasite density in first clinical episode 9. Geometric mean parasite density in parasitaemic children at 6.5 months 10. Geometric mean titre to CS protein and hepatitis B surface antigen (HBsAg) 11. Seropositivity for anti-CS antibody (> 0.5 international units/mL) and anti-hepatitis B surface antigen (HBsAg) antibody (≥ 10 international units/mL) 12. Adverse events Notes Location: Ilha Josina, a lowland area 55 km north of Manhica, Mozambique with pronounced seasonality of transmission and more intense transmission than in Manhica Method of surveillance: active surveillance for infection by morbidity questionnaire, axillary temperature, and blood slides at home visits starting 2 weeks after dose 3, every 2 weeks for 2.5 months then monthly for 2 months; observation for 1 h after vaccination and once/day at home for 3 days after each dose for adverse events; complete blood count done 1 month after dose 3; creatinine, alanine aminotransferase (ALT), and bilirubin at months 1 and 6.5 after dose 3; cross-sectional surveys with blood slide and axillary temperature taken at 6.5 months and 18 months after dose 3 This trial reported in same publication as Alonso 2005a
Bojang 2001
Methods Randomized controlled trial Generation of allocation sequence: externally generated list; in village blocks Allocation concealment: each individual's vaccine doses were packaged in sealed boxes labelled with a unique randomization number; vaccines given by nurses with no other role in study Inclusion criteria: age 6 to 11 years; no clinically significant chronic or acute disease (chronic hepatitis B carriers were not excluded) Exclusion criteria: known allergy to any vaccine; severe malnutrition (weight for height < 3 Z scores); haematocrit < 30% Interventions 1. RTS,S/AS02A vaccine: 10 µg in 0.1 mL adjuvant; 3 doses at 0, 1, and 3 month intervals 2. RTS,S/AS02A vaccine: 25 µg in 0.25 mL adjuvant; 3 doses at 0, 1, and 3 month intervals 3. RTS,S/AS02A vaccine: 50 µg in 0.5 mL adjuvant; 3 doses at 0, 1, and 3 month intervals 4. Rabies human diploid cell vaccine (Merieux HDCV): single-dose vial with diluent; 3 doses 0, 1, and 3 month intervals plus dose 4 given after trial completion (RTS,S groups were also offered 3 doses of rabies vaccine after trial completion) Increasing doses of vaccine were given in a dose-escalating fashion, ie dose groups were staggered at 10 day intervals Exclusion criteria: known allergy to any vaccine; severe malnutrition (weight for height < 3 Z scores); haematocrit < 30% Interventions 1. RTS,S/AS02A vaccine: 10 µg in 0.1 mL adjuvant; 3 doses at 0, 1, and 3 month intervals 2. RTS,S/AS02A vaccine: 25 µg in 0.25 mL adjuvant; 3 doses at 0, 1, and 3 month intervals 3. RTS,S/AS02A vaccine: 50 µg in 0.5 mL adjuvant; 3 doses at 0, 1, and 3 month intervals 4. Rabies human diploid cell vaccine (Merieux HDCV): single-dose vial with diluent; 3 doses at 0, 1, and 3 month intervals plus dose 4 given after trial completion; (vaccine groups were also offered 3 doses of rabies vaccine after trial completion) Increasing doses of vaccine were given in a dose-escalating fashion, ie dose groups were staggered at 10 day intervals Plasmodium falciparum in indirect fluorescent antibody test; history of severe reactions or allergy to mosquito bites, artemether-lumefantrine (Riamet), or vaccines; pregnancy or lactation; confirmed or suspected immunodeficient condition; chronic or active neurological, gastrointestinal, cardiovascular, or respiratory disease; haemoglobinopathies; history of > 2 hospitalizations for invasive bacterial infections; requirement of any chronic medication; suspected or known current alcohol or illegal drug abuse (excluding cannabis); any other significant finding which, in the opinion of the investigator, would significantly increase the risk of having an adverse outcome from participating in this protocol or of dropping out of the study; body mass index < 18 kg/m2 or > 32 kg/m2; evidence of past or present psychiatric condition; seropositivity for human immunodeficiency virus (HIV), hepatitis C or B (other than antibody to hepatitis B surface antigen (HBsAg)); 10-year risk of coronary heart disease > 10%; clinically significant deviation from normal range in biochemistry or haematology blood tests or in urinalysis Challenge by bite of 5 sporozoite-infected mosquitoes in Nijmegen, the Netherlands, 2 weeks after dose 2 Methods of surveillance: for adverse events, used diary card for self report of symptoms up to day 4, and solicited and unsolicited events assessed on days 4 and 14 after each dose; for efficacy, participants were seen once per day from day 3 to 5 after challenge, twice per day from day 6 to 15, and once per day from day 15 to 21
Guiguemde 1990
Methods Randomized controlled trial Generation of allocation sequence: stated to be randomized, but method not clear Allocation concealment: unclear Blinding: double blind Inclusion of all randomized participants: 109/123 (88.6%) infants completed the study Length of follow up: 5 months Participants Number: 123 infants Inclusion criteria: age 3 to 5 months; weight > 3 kg; good general health; parents' consent Exclusion criteria: fever ≥ 38°C; positive blood slide for Plasmodium falciparum 
